



Radiance Biopharma to Participate in 2025 BIO CEO & Investor Conference

NEW YORK, NY, UNITED STATES, February 10, 2025 /EINPresswire.com/ -- Radiance Biopharma, a biotechnology company developing next generation Antibody Drug Conjugates (ADCs), announced it will attend and schedule meetings at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at the New York Marriott Marquis in New York City.

Management will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees. Conference attendees that would like to schedule a meeting with the Company's management are encouraged to register through the BIO CEO attendee portal.

About Radiance Biopharma

Radiance is a biotechnology company developing next generation Antibody Drug Conjugates (ADCs) for the treatment of cancer. RB-164, is a 'Best in Class', anti-ROR-1 ADC, for the treatment of liquid and solid tumors. RB-201, is a 'First in Class' anti- HER2/TROP2 Bispecific ADC, utilizing next generation tandem linker-payload technology, for the treatment of solid tumors.

Contacts For more information, please visit www.radiancebiopharma.com Contact us at Info@radiancebiopharma.com Office Tel. 617.621.7143

Robert Brooks
Radiance Biopharma
[email us here](#)

Visit us on social media:
[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/784090661>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.